Niccolo' Bertini

Dr. Niccolo' Bertini

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
CBCarlotta Becherini
Carlotta Becherini
Andrea LanciaAndrea Lancia
Andrea Lancia
BDBeatrice Detti
Beatrice Detti
SLSARA LUCIDI
SARA LUCIDI
DSDaniele Scartoni
Daniele Scartoni
LLLorenzo Livi
Lorenzo Livi
Objective: Tumor-associated macrophages (TAMs) are the most represented cells of the immune system in the tumor microenvironment (TME). Besides its effects on cancer cells, radiation therapy (RT) can alter TME composition. With this systematic review, we provide a better understanding on how RT can regulate macrophage characterization, namely the M1 antitumor and the M2 protumor polarization, with the aim of describing new effective RT models and exploration of the possibility of integrating radiation with other available therapies. Methods: A systematic search in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was carried out in PubMed, Google Scholar, and Scopus. Articles from January 2000 to April 2020 which focus on the role of M1 and M2 macrophages in the response to RT were identified. Results: Of the 304 selected articles, 29 qualitative summary papers were included in our analysis (16 focusing on administration of RT and concomitant systemic molecules, and 13 reporting on RT alone). Based on dose intensity, irradiation was classified into low (low-dose irradiation, LDI; corresponding to less than 1 Gy), moderate (moderate-dose irradiation, MDI; between 1 and 10 Gy), and high (high-dose irradiation, HDI; greater than 10 Gy). While HDI seems to be responsible for induced angiogenesis and accelerated tumor growth through early M2-polarized TAM infiltration, MDI stimulates phagocytosis and local LDI may represent a valid treatment option for possible combination with cancer immunotherapeutic agents. Conclusion: TAMs seem to have an ambivalent role on the efficacy of cancer treatment. Radiation therapy, which exerts its main antitumor activity via cell killing, can in turn interfere with TAM characterization through different modalities. The plasticity of TAMs makes them an attractive target for anticancer therapies and more research should be conducted to explore this potential therapeutic strategy.

4 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
IMIlaria Morelli
Ilaria Morelli
MBMarco Banini
Marco Banini
DGDaniela Greto
Daniela Greto
LVLuca Visani
Luca Visani
PGPietro Garlatti
Pietro Garlatti
IDIsacco Desideri
Isacco Desideri
Purpose: This systematic review aims to analyze the literature on the application of AI in predicting patient outcomes and treatment-related toxicity in those undergoing SBRT or SRS across heterogeneous tumor sites. Materials and methods: Our review conformed to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PubMed, EMBASE and Scopus were systematically searched for English-language human studies evaluating AI for outcome and toxicity prediction in patients undergoing SBRT or SRS for solid tumors. Search terms included (“Stereotactic Body Radiotherapy” OR “SBRT” OR “Stereotactic Radiosurgery” OR “SRS” OR “Stereotactic Ablative Radiotherapy” OR “SABR”) AND (“Artificial Intelligence” OR “AI” OR “Machine Learning” OR “Deep Learning” OR “Radiomics”) AND (“Response Prediction” OR “Response to Treatment” OR “Outcome Prediction”) AND (“Toxicity” OR “Side Effects” OR “Treatment Toxicities” OR “Adverse Events”). Results: The search yielded 29 eligible retrospective studies, published between 2020 and 2025. Eight studies addressed early-stage primary lung cancer, highlighting the potential of AI-based models in predicting radiation-induced pneumonitis, fibrosis and local control. Five studies investigated AI models for predicting hepatobiliary toxicity following SBRT for liver tumors. Sixteen studies involved SRS-treated patients with brain metastases or benign intracranial neoplasms (e.g., arteriovenous malformations, vestibular schwannomas, meningiomas), exploring AI algorithms for predicting treatment response and radiation-induced changes. In the results, AI might have been exploited to both reaffirm already known clinical predictors and to identify novel imaging, dosimetric or biological biomarkers. Examples include predicting radiation pneumonitis in lung cancer, residual liver function in hepatic tumors and local recurrence in brain metastases, thus supporting tailored treatment decisions. Conclusions: Combining AI with SBRT could greatly enhance personalized cancer care by predicting patient-specific outcomes and toxicity. AI models analyze complex datasets, including imaging and clinical data, to identify patterns that traditional methods may miss, thus enabling more accurate risk stratification and reducing variability in treatment planning. With further research and clinical validation, this integration could make radiotherapy safer, more effective and contribute to advancement in precision oncology.

19 February 2024 in La radiologia medica
Verified
Journal Article
Open access
PDF file
Gianluca IngrossoGianluca Ingrosso
Gianluca Ingrosso
EPElisabetta Ponti
Elisabetta Ponti
GFGiulio Francolini
Giulio Francolini
Saverio CainiSaverio Caini
Saverio Caini
SFSimona Fondelli
Simona Fondelli
BDBeatrice Detti
Beatrice Detti
Background: Moderate hypofractionated radiotherapy is a treatment option for the cure of localized prostate cancer (PCa) patients based on the results of randomized prospective trials, but there is a clinical concern about the relatively short length of follow-up, and real-world results on outcome and toxicity based on cutting-edge techniques are lacking. The objective of this study is to present the long-term results of a large multicentric series. Materials and methods: We retrospectively evaluated 1325 PCa patients treated with daily volumetric image-guided hypofractionated radiotherapy between 2007 and 2020 in 16 Centers. For survival endpoints, we used Kaplan–Meier survival curves and fitted univariate and multivariable Cox’s proportional hazards regression models to study the association between the clinical variables and each survival type. Results: At the end of the follow-up, 11 patients died from PCa. The 15-year values of cancer-specific survival (CSS) and biochemical relapse-free survival (b-RFS) were 98.5% (95%CI 97.3–99.6%) and 85.5% (95%CI 81.9–89.4%), respectively. The multivariate analysis showed that baseline PSA, Gleason score, and the use of androgen deprivation therapy were significant variables for all the outcomes. Acute gastrointestinal (GI) and genitourinary (GU) toxicities of grade ≥ 2 were 7.0% and 16.98%, respectively. The 15-year late grade ≥ 2 GI and GU toxicities were 5% (95%CI 4–6%) and 6% (95%CI 4–8%), respectively. Conclusion: Real-world long-term results of this multicentric study on cutting-edge techniques for the cure of localized PCa demonstrated an excellent biochemical-free survival rate of 85.5% at 15 years, and very low rates of ≥ G3 late GU and GI toxicity (1.6% and 0.9% respectively), strengthening the results of the available published trials.

9 January 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
BSBianca Santo
Bianca Santo
NBNiccolo' Bertini
Niccolo' Bertini
CCCarlo Guglielmo Cattaneo
Carlo Guglielmo Cattaneo
SMSara De Matteis
Sara De Matteis
PFPaola De Franco
Paola De Franco
VSViola Salvestrini
Viola Salvestrini

17 November 2025 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
NBNiccolo' Bertini
Niccolo' Bertini
HGHubert S. Gabryś
Hubert S. Gabryś
HAHatem Alkadhi
Hatem Alkadhi
LWLotte Wilke
Lotte Wilke
PWPatrick Wohlfahrt
Patrick Wohlfahrt
PBPanagiotis Balermpas
Panagiotis Balermpas
Photon-counting detector computed tomography (PCD-CT) offers advancements over conventional energy-integrating detector computed tomography (EID-CT). This study is the first to investigate the use of PCD-CT for delineation purposes. Twelve patients with head-and-neck cancer were prospectively included. Delineation of clinical target volume (CTV) and organs at risk (OARs) was performed by three physicians using EID-CT (120 kVp) and PCD-CT at virtual monoenergetic levels of 140 keV and 50 keV. Segmentation accuracy was assessed and contouring-confidence was rated. The ratio of the mean computed tomography dose index (CTDI) for EID-CT/PCD-CT for all patients was 2.72. The study revealed high inter-observer agreement for the mandible, oral cavity, parotid glands, and submandibular glands, with DSCs exceeding 0.8 across both EID-CT and PCD-CT. No differences in delineation agreement were observed, while a significant improvement was found for the lips (p = 0.001) and oral cavity (p = 0.003) when combining 140 keV and 50 keV images in PCD-CT compared to EID-CT. PCD-CT outperformed EID-CT in terms of contouring confidence. The study established the feasibility of PCD-CT for radiotherapy planning. PCD-CT-based delineation provides results comparable to EID-CT, with the added advantages of reduced radiation dose, improved image quality and higher delineation confidence. Significant improvements in delineating specific structures, such as the lips and oral cavity, were observed when combining multiple energy levels in PCD-CT.

23 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NBNiccolo' Bertini
Niccolo' Bertini
GFGiulio Francolini
Giulio Francolini
VCVanessa Di Cataldo
Vanessa Di Cataldo
PGPietro Garlatti
Pietro Garlatti
MAMichele Aquilano
Michele Aquilano
LLLorenzo Livi
Lorenzo Livi
Purpose/Objectives: Salvage radiotherapy (SRT) after a radical prostatectomy is a curative approach for patients with biochemical recurrence (BR). However, outcomes are often less favorable when imaging reveals macroscopic local recurrence. In such cases, dose escalation through stereotactic salvage radiotherapy (SSRT) may offer improved disease control. The STARR trial (NCT05455736) is a prospective, multicenter study evaluating the efficacy and safety of SSRT in patients with macroscopic prostate bed recurrence. This interim analysis reports early findings from the initial patient cohort. Materials and Methods: Patients with BR (PSA > 0.2 ng/mL) post-prostatectomy and PET-confirmed macroscopic recurrence (PSMA or Choline PET, confirmed by MRI) were eligible. Treatment involved CyberKnife®-based SSRT delivering 35 Gy in five fractions to the visible lesion. Androgen deprivation therapy (ADT) was not permitted. Complete biochemical response (CBR) was defined as PSA < 0.2 ng/mL, and biochemical response (BR) as a ≥50% PSA reduction. Additional outcomes included biochemical, radiological, and ADT-free survival (bPFS, rPFS, aPFS). Results: As of analysis, 51 patients were enrolled, with a median follow-up of 16 months (95% CI: 16–22). CBR and BR were achieved in 45.1% and 80.4% of patients, respectively. Events affecting bPFS, rPFS, and aPFS occurred in 12, 5, and 6 patients, with median values not yet reached. Toxicity was minimal, with two cases each of acute grade 2 GI and GU events, and one late grade 2 GI event. No grade ≥ 3 toxicities were reported. Conclusion: Early data support SSRT as a safe and a promising option for macroscopic local recurrence, with encouraging response rates and minimal toxicity.